On Thursday, in the U.S. Supreme Court’s first abortion decision since the overturning of Roe v. Wade, the court unanimously preserved access to the drug used in nearly two-thirds of all abortions last year.

Maine Gov. Janet Mills and Attorney General Aaron Frey both welcomed the outcome, which does not work against their efforts to simplify and protect access to the drug, mifepristone. Last year, in the face of growing and increasingly creative penalization of abortion and miscarriage management (the case rejected by the Supreme Court came from a group of doctors who rallied together to challenge the regulatory status of mifepristone), Maine joined 17 other states in a lawsuit against the Food and Drug Administration’s restrictions on it.

In her statement following the ruling, Mills took care not to sound complacent. “While this ruling is welcome news, we know this: the reproductive rights of women remain under direct and constant attack, and I pledge that my administration will continue to fight any attempts to undermine reproductive rights in Maine.”

Sadly, this remains an accurate reading of the room. Although the American voting public has repeatedly made known its support for access to abortion and reproductive health care, the forces devoted to its limitation (or, indeed, its elimination) appear unbowed.

For now, Maine’s leaders are fortunate to have federal leaders on their side in this respect. Mills’ statement echoed that of U.S. Attorney General Merrick Garland, who said: “The Department of Justice is committed to protecting reproductive freedom. We will continue to use every tool at our disposal to protect women’s access to mifepristone and other lawful reproductive care.”

This latest Supreme Court decision changes little. November, on the other hand, could change plenty.